Latest news

• Novartis launches first biosimilar Zarxio in the US

  therapies.”. Biosimilars have been available in Europe since 2006 and Zarxio is already available in more than 40 countries under the brand name Zarzio, where it has captured around 30% of

• Apotex latest to file Neupogen biosimilar in the US

  the brand name Zarzio.

• FDA close to first biosimilar approval

  US under the brand name Zarzio.

• Biosimilars could make EU big cost savings after slow start

  In the case of Amgen's once-daily white blood cell stimulator Neupogen (filgrastim), however, the drug has now been overtaken by its biosimilar rivals - led by Sandoz' Zarzio - and the

• FDA 'must publish biosimilar naming guide soon'

  as Zarzio - in Europe in 2009. ... According to the company Zarzio is the leading G-CSF in Europe with a 30 per cent market share.